Pieris Pharmaceuticals Inc (PIRS) News

Form 425 - Prospectuses and communications, business combinations

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical...

Form 425 - Prospectuses and communications, business combinations

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 3 - Initial statement of beneficial ownership of securities

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc. PR Newswire NEW YORK, July 24, 2024 NEW YORK, July...

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report